Studies protein and gene patterns in breast cancer tumours
Examines tumour proteins and receptor genes in adults with primary or recurrent breast cancer.
Plain-language title generated from the registry record
Registry title: Breast Cancer Proteomics and Molecular Heterogeneity
Key facts
- Where
- Cork, Dublin, Limerick, and Waterford, IrelandSee the 6 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adult women with a new breast cancer, or with breast cancer that came back or spread. They go to hospital to have tumour tissue taken out, tested or treated.
- Age
- 18 years or older
- Sex
- Women only
- Disease stage
- Primary breast cancer, or suspected or confirmed recurrent or metastatic breast cancer, or suspected newly diagnosed stage 4 breast cancer
- Earlier treatment
- People having treatment before surgery (neoadjuvant treatment) can also join, if this applies
Main reasons for not taking part
- People who cannot give informed consent
Read by machine on 9 November 2026.
Where in Ireland
- Cork University HospitalCork, IrelandTaking people
- Beaumont HospitalDublin, IrelandTaking people
- St Vincent's University HospitalDublin, IrelandTaking people
- St. James's HospitalDublin, IrelandNo longer taking part
- University Hospital LimerickLimerick, IrelandNo longer taking part
- University Hospital WaterfordWaterford, IrelandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Cancer Trials Ireland
- Trial code
- NCT01840293
- Record updated
- 19 December 2025
- Original description
Primary objective:Read full original descriptionShow less
Breast Cancer Proteomics and Molecular Heterogeneity
Primary objective:
The primary objective is to define the proteomic and molecular characteristics of primary and recurrent/ metastatic breast tumours with special focus on the expression of S100 protein and the estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2) genes
Secondary objective:
* To expand our understanding of the complex molecular pathways dictating the progression of breast cancer and their response to different treatment regimes. * To relate proteomic findings to survival data * To identify potential serum markers of breast cancer progression
Inclusion: Patients diagnosed with primary breast cancer attending hospital for the resection of their tumour tissue; Or; -Patients with suspected or confirmed recurrent or metastatic breast cancer (Patient has a history of a biopsy- or surgically- (i.e. pathologically) confirmed primary breast cancer) attending hospital for the resection/biopsy and/or treatment of tumour tissue; Or; -Patient with suspected (but not necessarily biopsy confirmed) newly diagnosed stage 4 breast cancer attending hospital for the resection/biopsy and/or treatment of their tumour tissue; Patients receiving neoadjuvant treatment are also eligible (if applicable); Patients have to be ≥ 18 years of age; Patients must be able to give informed consent.